AbCellera Biologics Inc.
ABCL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.68 | 0.06 | 0.00 | 0.94 |
| FCF Yield | -21.68% | -7.35% | 7.09% | 4.72% |
| EV / EBITDA | -3.78 | -8.30 | 9.49 | 14.52 |
| Quality | ||||
| ROIC | -19.85% | -14.51% | 10.05% | 11.91% |
| Gross Margin | -236.42% | 18.75% | 86.31% | 87.87% |
| Cash Conversion Ratio | 0.67 | 0.30 | 1.75 | 1.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -60.98% | -53.38% | 27.69% | 218.51% |
| Free Cash Flow Growth | -54.02% | -159.30% | 9.98% | 2,221.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 0.29 | -1.12 | -1.80 |
| Interest Coverage | 0.00 | 0.00 | 53.53 | 39.12 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 27.91 | 43.37 | 27.22 |
| Cash Conversion Cycle | 1,037.03 | 329.70 | -44.03 | 49.94 |